Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
1 clinical trials · Condition
◉ Watch Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1)
| Record | Firm | Date |
|---|---|---|
| Efficacy and Safety Study of First-line Treatment With SG001 Plus Chemotherapy ± Bevacizumab Versus Placebo Plus Chemotherapy ±Bevacizumab for Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) (NCT05715840) | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | 2023-01-31 |
Track Recurrent, or Metastatic Cervical Cancer With PD-L1 Positive (CPS≥1) automatically
Every clearance here is in the API, with alerts when new ones post.